Home > Compound List > Compound details
151-83-7 molecular structure
click picture or here to close

5-(hex-3-yn-2-yl)-1-methyl-5-(prop-2-en-1-yl)-1,3-diazinane-2,4,6-trione

ChemBase ID: 357
Molecular Formular: C14H18N2O3
Molecular Mass: 262.30432
Monoisotopic Mass: 262.13174245
SMILES and InChIs

SMILES:
O=C1N(C(=O)NC(=O)C1(C(C)C#CCC)CC=C)C
Canonical SMILES:
CCC#CC(C1(CC=C)C(=O)NC(=O)N(C1=O)C)C
InChI:
InChI=1S/C14H18N2O3/c1-5-7-8-10(3)14(9-6-2)11(17)15-13(19)16(4)12(14)18/h6,10H,2,5,9H2,1,3-4H3,(H,15,17,19)
InChIKey:
NZXKDOXHBHYTKP-UHFFFAOYSA-N

Cite this record

CBID:357 http://www.chembase.cn/molecule-357.html

Collapse All Expand All

NAMES AND DATABASE IDS

NAMES AND DATABASE IDS

Names Database IDs
IUPAC name
5-(hex-3-yn-2-yl)-1-methyl-5-(prop-2-en-1-yl)-1,3-diazinane-2,4,6-trione
IUPAC Traditional name
methohexital sodium
methohexital
Brand Name
Brevital
Brevital sodium
Brietal
Synonyms
Methodrexitone
Methohexitone
Methohexital
1-Methyl-5-(1-methyl-2-pentyn-1-yl)-5-(2-propen-1-yl)-2,4,6(1H,3H,5H)-pyrimidinetrione
5-Allyl-5-(3-hexyn-2-yl)-1-methylbarbituric Acid
Brevital
Brietal
Compound 22451
Compound 25398
Enallynymall
CAS Number
151-83-7
PubChem SID
46507954
160963820
PubChem CID
9034
CHEBI ID
102216
ATC CODE
N05CA15
N01AF01
CHEMBL
7413
Chemspider ID
8683
DrugBank ID
DB00474
KEGG ID
D04985
Unique Ingredient Identifier
E5B8ND5IPE
Wikipedia Title
Methohexital

DATA SOURCES

DATA SOURCES

All Sources Commercial Sources Non-commercial Sources
Data Source Data ID Price
TRC
M260650 external link Add to cart Please log in.

CALCULATED PROPERTIES

CALCULATED PROPERTIES

JChem ALOGPS 2.1
Acid pKa 8.731305  H Acceptors
H Donor LogD (pH = 5.5) 2.2865314 
LogD (pH = 7.4) 2.2672198  Log P 2.2867832 
Molar Refractivity 71.5071 cm3 Polarizability 26.970406 Å3
Polar Surface Area 66.48 Å2 Rotatable Bonds
Lipinski's Rule of Five true 
Log P 2.43  LOG S -3.7 
Solubility (Water) 5.24e-02 g/l 

PROPERTIES

PROPERTIES

Physical Property Safety Information Pharmacology Properties Product Information Bioassay(PubChem)
Hydrophobicity(logP)
1.8 expand Show data source
MSDS Link
Download expand Show data source
Admin Routes
Intravenous, rectal expand Show data source
Bioavailability
I.V. ~100%
Rectal ~17%
expand Show data source
Half Life
5.6 ± 2.7 minutes expand Show data source
Metabolism
Hepatic expand Show data source
Legal Status
Schedule IV expand Show data source
Pregnancy Category
B (USA) expand Show data source
Certificate of Analysis
Download expand Show data source

DETAILS

DETAILS

DrugBank DrugBank Wikipedia Wikipedia TRC TRC
DrugBank - DB00474 external link
Item Information
Drug Groups approved
Description An intravenous anesthetic with a short duration of action that may be used for induction of anesthesia. [PubChem]
Indication Methohexital is indicated for use as an intravenous anaesthetic. It has also been commonly used to induce deep sedation.
Pharmacology Methohexital, a barbiturate, is used for the induction of anesthesia prior to the use of other general anesthetic agents and for induction of anesthesia for short surgical, diagnostic, or therapeutic procedures associated with minimal painful stimuli. Little analgesia is conferred by barbiturates; their use in the presence of pain may result in excitation.
Toxicity The onset of toxicity following an overdose of intravenously administered methohexital will be within seconds of the infusion. If methohexital is administered rectally or is ingested, the onset of toxicity may be delayed. The manifestations of an ultrashort-acting barbiturate in overdose include central nervous system depression, respiratory depression, hypotension, loss of peripheral vascular resistance, and muscular hyperactivity ranging from twitching to convulsive-like movements. Other findings may include convulsions and allergic reactions. Following massive exposure to any barbiturate, pulmonary edema, circulatory collapse with loss of peripheral vascular tone, and cardiac arrest may occur.
Affected Organisms
Humans and other mammals
Biotransformation Metabolism occurs in the liver through demethylation and oxidation. Side-chain oxidation is the most important biotransformation involved in termination of biologic activity.
Absorption The absolute bioavailability following rectal administration of methohexital is 17%.
Half Life 5.6 ± 2.7 minutes
Protein Binding 73%
Elimination Excretion occurs via the kidneys through glomerular filtration.
External Links
Wikipedia
RxList
Drugs.com
Toronto Research Chemicals - M260650 external link
Methohexital is a short-acting barbiturate used as a sedative. Methohexital is used an anesthetic for oral surgery and dentistry and is also used to induce anesthesia prior to electroconvulsive therapy (ECT). Methohexital is a Controlled Substance.

REFERENCES

REFERENCES

From Suppliers Google Scholar IconGoogle Scholar PubMed iconPubMed Google Books IconGoogle Books
  • • Avramov, M.N. et al.: Anesth. Analges., 81, 596 (1995)
  • • Hamid, S.K. et al.: Br. J. Anaesth., 77, 727 (1995)
  • Searching...Please wait...

PATENTS

PATENTS

PubChem iconPubChem Patent Google Patent Search IconGoogle Patent

INTERNET

INTERNET

Baidu iconBaidu google iconGoogle